P I Industries Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Revenue hit by a perfect storm, but margins held: AgChem exports and domestic both declined as prolonged rains, Chinese price deflation, and regulatory disruption converged. Yet gross margin expanded ~500 bps on mix, and management reaffirmed its full-year EBITDA guidance.
• The recovery keeps sliding right: A modest Q4 FY26 uptick is still the base case, but a full industry recovery is now pushed to the second half of 2026 or later, and management declined to guide on FY27, calling it too early.
• Pharma doubled, but it is still an investment story: H1 pharma revenue doubled YoY on new client wins and six late-stage programs, yet the segment remains EBITDA-negative and will stay in investment mode for another year or so.
• Biologicals is the big bet, with a long fuse: Management called biologicals the next growth driver for the industry and targets a three- to four-fold increase, but near-term sales are stalled by Indian regulatory approvals and margins are explicitly not a focus for the next few years.
• What to watch next quarter: Whether domestic biologicals sales actually resume in Q4 as guided, the pace of export order book conversion into revenue, and any firming of FY27 visibility ahead of formal guidance.

Demand & Revenue Headwinds

• AgChem exports declined on volume: The drop was in line with customer delivery schedules and deferments, as global innovators balanced inventory. Management characterized it as transitional softness built into the FY26 plan.
• Domestic business hit by weather and regulation: Erratic, prolonged rains negated a positive Kharif start, while abrupt regulatory changes on biologicals and a fertiliser shortfall spoiled growth momentum. Higher channel inventory and credit levels added pressure.
• Global industry still in a down-cycle: Most global innovators reported 3% to 5% H1 revenue declines, with cautious volume-led recovery guidance for H2. Destocking has occurred in many geographies, but normalization of restocking is expected only in the next 2 to 3 quarters.
• U.S. tariff uncertainty is a new overhang: The company is not seeing much direct impact yet, but uncertainty is creating a slowdown in decision-making across both agchem and pharma sectors.

Mayank Singhal: "FY26 is expected to see a modest recovery in Q4, a full recovery is not expected to realise before 2nd half of 2026 or later."

Margin & Balance Sheet Resilience

• Gross margin expanded sharply: A roughly 500 bps increase was driven primarily by favourable product mix and operating efficiencies. Management reiterated that 50% to 52% gross margin is a sustainable level on a longer-term basis.
• EBITDA guidance reaffirmed despite top-line pressure: Management stated it will keep to its earlier annual EBITDA guidance, citing the product-mix benefit this quarter.
• Contract assets swelled on deferred deliveries: A ₹450 crore increase represents finished goods produced exclusively for customers with confirmed orders, with deliveries lined up over the next 1 to 2 quarters. Revenue has already been recorded per accounting standards.
• Trade working capital expected to normalize: Improvement is anticipated as the market scenario normalizes in coming quarters.

Mayank Singhal: "Well, as we have given the annual guidance given the top line challenges, this quarter has been good because of the given product mix, as we mentioned. So, we will keep to our guidance as earlier."

Pharma CDMO: Scaling Up, Not Yet Profitable

• Revenue doubled in H1: Growth was driven by deepening relationships with biotech and big pharma innovators, with business development teams now in place in the US and Europe.
• Two new clients onboarded in H1: The pipeline includes six late-stage programs spanning Phase I through Phase III.
• Investment phase to continue for another year or so: The company is building capabilities, strengthening people and processes, reflected in higher overheads. Management expects to reach a scale that can sustain profitable growth and achieve positive EBITDA in the next 1 year.
• Q2 profitability dipped: PBT margins saw a slight decline due to one-off waste processing-related costs, unfavourable product mix, and higher overheads from capability building and people costs.

Biologicals: The Long-Game Growth Driver

• Positioned as the industry's next growth engine: Management noted biologicals have been growing at double digits for the last 5 years while chemicals grew at 2% to 3%, and expects that divergence to continue for the next 5 to 10 years. The company's peptide platform was cited as a key differentiator.
• Targeting a three- to four-fold increase: On the global platform, once regulatory hurdles are crossed, management expects at least 25-plus percent CAGR growth.
• Indian sales stalled by regulatory disruption: The domestic biologicals business was under a restricted category for most of H1. The ban has been sorted out, but the company is still in the regulatory phase of getting documentation procedures and state-level approvals. Sales are expected to resume from Q4 FY26.
• Margins are explicitly not the near-term focus: Management stated that for the next few years, the priority is scaling up the business, not looking at margins.
• New Hyderabad research centre commissioned: The centre will study plant systems and support the global biological research centre in Seattle.

Rajnish Sarna: "My view is that as far as margins are concerned, for next few years, we should only be focusing on scaling up this business and not looking at margins."

New Product Engine & Diversification

• 5 to 6 products commercialized in H1 FY26: Primarily on the agri side of the CSM business. Another 5 to 6 are planned for H2, with a mix of both agrochemicals and non-AgChem products. Ramp-up to full scale takes 3 to 5 years.
• Non-AgChem pipeline building: Current development pipeline includes molecules in electronic chemicals and specialty chemicals categories. Five to six electronic chemical products have already been commercialized over the last few years, with a few more expected in the current year.
• Over 20 new products in the development pipeline: Scheduled for future development and registration. Three new domestic brands were introduced in H1, with three more planned later this year.
• Own NCE on track for first Indian registration: A large number of field trials have been conducted in India, and product development work is ongoing.
• Inorganic opportunities being evaluated: The company is looking at several opportunities in the domestic market and in other technology areas outside India.

Guidance & Commitments

Key Metrics